4.4 Article

Rapid Arc-SBRT: Non-Invasive Immune Adjuvant for Advanced Stage Non-Small

Journal

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 22, Issue 2, Pages 202-205

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1871520621666210322105641

Keywords

SBRT; macrophage polarization; immune adjuvant; lung cancer; tumor therapy

Ask authors/readers for more resources

The Ra-SBRT technique offers a therapeutic advantage for the treatment of advanced-stage NSCLC by reducing bystander toxicity to normal tissues and promoting tumor immune rejection.
In conjunction with radio-chemotherapy, pulmonary resection is recommended for early-stage nonsmall-cell lung carcinoma but not for advanced-stage NSCLC patients having high-grade metastatic lesions. In these cases, the rapid Arc-Stereotactic body radiotherapy (Ra-SBRT) technique offers a therapeutic advantage by delivering focal irradiation to metastatic lung lesions and reduces the bystander toxicity to normal tissues. We have previously demonstrated that Ra-SBRT ablates metastatic lesions and induces tumor immune rejection of metastatic tumors by promoting in situ programming of M2 TAM towards M1-TAM and infiltration of Siglec-8+ Eosinophils. Most interestingly, Ra SBRT has very low abscopal impact and spares normal tissues, which are the significant limitations with conventional radiotherapy. In view of this and the immune adjuvant potential of Ra SBRT, it promotes normalization of aberrant vasculature and inhibits the metastatic potential of NSCLC lesions. In view of this, we here propose that Ra-SBRT indeed represents an immunogenic approach for the effective management of advanced-stage NSCLC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available